NASDAQ · Financial Statements

Ironwood Pharmaceuticals, Inc. (IRWD) Revenue, Earnings & Financial Statements

$4.87 NASDAQ: IRWD Market Cap $806.23M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Ironwood Pharmaceuticals, Inc. most recently reported annual revenue of $296.0M, net profit of $24.0M. Revenue declined at an average annual rate of 5.4% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Ironwood Pharmaceuticals, Inc.: Revenue rose from $274.0M in 2016 to $296.0M in 2025, a change of +8.0% over 9 years; net profit was positive in 6 of 10 reported years; operating margin moved from -18.9% to 40.1%, a shift of +59.0 percentage points; the most recent year shows net profit of $24.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$274.0M$298.0M$347.0M$428.0M$390.0M$414.0M$411.0M$443.0M$351.0M$296.0M
Operating Expenses$326.0M$376.0M$586.0M$308.0M$247.0M$181.0M$160.0M$1.4B$258.0M$177.0M
Operating Profit−$52.0M−$77.0M−$239.0M$120.0M$143.0M$232.0M$250.0M−$945.0M$93.0M$119.0M
Operating Margin-18.9%-25.9%-68.9%28.0%36.7%56.1%61.0%-213.5%26.5%40.1%
Other Income−$30.0M−$71.0M−$43.0M−$61.0M−$34.0M−$32.0M$2.0M−$3.0M−$28.0M−$49.0M
Interest$39.0M$36.0M$38.0M$37.0M$29.0M$31.0M$8.0M$22.0M$33.0M$33.0M
Depreciation$11.0M$15.0M$12.0M$6.0M$4.0M$2.0M$1.0M$2.0M$2.0M$2.0M
Profit Before Tax−$82.0M−$117.0M−$282.0M$59.0M$109.0M$201.0M$252.0M−$948.0M$65.0M$70.0M
Tax rate (%)0.0%-29.3%2.0%0.0%2.5%-163.4%30.6%-8.8%98.7%65.7%
Net Profit−$82.0M−$117.0M−$282.0M$22.0M$106.0M$528.0M$175.0M−$1.0B$1.0M$24.0M
EPS−$0.56−$0.78−$1.85$0.38$0.66$3.21$0.96−$6.45$0.01$0.15

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$118.0M$75.0M$94.0M$92.0M$91.0M$41.0M$85.0M$122.0M$48.0M$107.0M$113.0M$133.0M
Operating Expenses$80.0M$64.0M$69.0M$66.0M$59.0M$70.0M$40.0M$44.0M$41.0M$34.0M$34.0M$40.0M
Operating Profit$38.0M$11.0M$25.0M$26.0M$31.0M−$29.0M$45.0M$78.0M$7.0M$73.0M$79.0M$93.0M
Operating Margin32.0%14.7%26.5%28.0%34.8%-70.8%52.9%63.6%13.7%68.1%70.2%70.0%
Interest$8.0M$7.0M$7.0M$9.0M$9.0M$8.0M$8.0M$8.0M$8.0M$9.0M$7.0M$6.0M
Profit Before Tax$30.0M$5.0M$19.0M$17.0M$24.0M−$36.0M$38.0M$68.0M$0$65.0M$74.0M$88.0M
Tax rate (%)105.8%183.9%104.6%79.0%90.6%-3.1%37.6%41.1%600.2%37.4%30.4%31.7%
Net Profit−$1.0M−$4.0M−$1.0M$4.0M$2.0M−$37.0M$24.0M$40.0M−$2.0M$41.0M$51.0M$60.0M
EPS−$0.01−$0.03−$0.01$0.02$0.01−$0.23$0.14$0.23−$0.01$0.24$0.31$0.36

Over the 10 years reported for Ironwood Pharmaceuticals, Inc., borrowings increased from $373.0M in 2016 to $598.0M in 2025, cash stood at $215.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 1.13 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$710.0M$606.0M$332.0M$403.0M$559.0M$1.1B$1.1B$471.0M$351.0M$397.0M
Current Assets$380.0M$312.0M$266.0M$307.0M$496.0M$745.0M$781.0M$233.0M$182.0M$274.0M
Cash$54.0M$126.0M$173.0M$177.0M$364.0M$620.0M$656.0M$92.0M$89.0M$215.0M
Inventory$1.0M$1.0M$0$1.0M$0$0$1.0M$0$0$0
Receivables$65.0M$82.0M$81.0M$117.0M$122.0M$114.0M$115.0M$129.0M$82.0M$47.0M
Fixed Assets$21.0M$17.0M$17.0M$30.0M$26.0M$23.0M$20.0M$18.0M$16.0M$13.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$392.0M$211.0M$47.0M$0$37.0M$0$15.0M$0$0$0
Other Assets$1.0M$1.0M$1.0M$1.0M$0$0$0$0$0$0
Total Liabilities$643.0M$596.0M$528.0M$496.0M$497.0M$521.0M$448.0M$817.0M$652.0M$659.0M
Current Liabilities$91.0M$66.0M$120.0M$41.0M$32.0M$162.0M$26.0M$276.0M$39.0M$242.0M
Borrowings$373.0M$400.0M$414.0M$431.0M$454.0M$476.0M$416.0M$716.0M$599.0M$598.0M
Other Liabilities$270.0M$196.0M$114.0M$65.0M$43.0M$45.0M$32.0M$102.0M$53.0M$61.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$67.0M$10.0M−$196.0M−$93.0M$63.0M$606.0M$652.0M−$346.0M−$301.0M−$262.0M

For Ironwood Pharmaceuticals, Inc., operating cash flow was positive in 7 of 10 reported years; free cash flow in the latest year was $127.0M; free cash flow was positive in 7 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow−$25.0M−$100.0M−$71.0M$11.0M$169.0M$262.0M$274.0M$183.0M$104.0M$127.0M
Investing Cash Flow−$282.0M$147.0M$82.0M−$18.0M−$4.0M−$1.0M$0−$1.0B$0$0
Financing Cash Flow$25.0M$11.0M$32.0M−$21.0M$0−$5.0M−$117.0M−$29.0M−$3.0M$0
Net Cash Flow−$207.0M$72.0M$48.0M−$2.0M$186.0M$257.0M$36.0M−$566.0M−$4.0M$127.0M
Free Cash Flow−$130.0M−$104.0M−$80.0M$4.0M$167.0M$262.0M$274.0M$183.0M$103.0M$127.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA2.82
FCF Yield25.54%
Quick Ratio6.51
Interest Coverage8.27
Return 1Y54.94%
Return 3Y-50.26%
Return 5Y-60.02%

Ironwood Pharmaceuticals, Inc. (IRWD) financials — frequently asked questions

What is Ironwood Pharmaceuticals, Inc.'s annual revenue?

Ironwood Pharmaceuticals, Inc. (IRWD) reported annual revenue of $296.0M in its most recent fiscal year.

What is Ironwood Pharmaceuticals, Inc.'s net profit?

Ironwood Pharmaceuticals, Inc. (IRWD) reported net profit of $24.0M in its most recent fiscal year.

What is IRWD EV/EBITDA?

Ironwood Pharmaceuticals, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 2.82.

Revenue and earnings of other Drug Manufacturers - Specialty & Generic stocks

TEVA revenue $17.3BZTS revenue $9.5BVTRS revenue $14.3BELAN revenue $4.7BRDY revenue $353.5BALKS revenue $1.5BAMRX revenue $3.0BLNTH revenue $1.5BSUPN revenue $719.0MBHC revenue $10.3BAll Drug Manufacturers - Specialty & Generic stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
IRWD Overview IRWD Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.